MediciNova, Inc.

Report azionario NasdaqGM:MNOV

Capitalizzazione di mercato: US$65.0m

MediciNova Gestione

Criteri Gestione verificati 2/4

MediciNova Il CEO è Yuichi Iwaki, nominato in Jan2000, e ha un mandato di 26.42 anni. la retribuzione annua totale è $ 1.74M, composta da 37.9% di stipendio e 62.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.22% delle azioni della società, per un valore di $ 1.44M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9.9 anni e 6.3 anni.

Informazioni chiave

Yuichi Iwaki

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO37.85%
Mandato del CEO26.4yrs
Proprietà del CEO2.2%
Durata media del management9.9yrs
Durata media del Consiglio di amministrazione6.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Aug 28

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Apr 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Nov 27

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Jul 11

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 18

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.
Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.
Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.
Articolo di analisi • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Articolo di analisi • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.
Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time
Articolo di analisi • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yuichi Iwaki rispetto agli utili di MediciNova?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$2mUS$657k

-US$12m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$11m

Dec 31 2024US$1mUS$657k

-US$11m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$657k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$620k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$3mUS$596k

-US$10m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$587k

-US$14m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$12m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$4mUS$572k

-US$13m

Compensazione vs Mercato: La retribuzione totale di Yuichi ($USD 1.74M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 641.77K ).

Compensazione vs guadagni: La retribuzione di Yuichi è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Yuichi Iwaki (76 yo)

26.4yrs
Mandato
US$1,736,711
Compensazione

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006 and as Chairman. Dr. Iwaki served as Acting Principal Financial Off...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Yuichi Iwaki
Co-Founder26.4yrsUS$1.74m2.22%
$ 1.4m
Kazuko Matsuda
Senior VP14.8yrsUS$1.33m0.66%
$ 426.4k
David Crean
Chief Business Officer5.1yrsUS$120.00k0%
$ 0
Jason Kruger
CFO & Principal Financial Officer4yrsNessun datoNessun dato
9.9yrs
Durata media
60.5yo
Età media

Gestione esperta: Il team dirigenziale di MNOV è esperto e expertise (durata media dell'incarico 9.9 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Yuichi Iwaki
Co-Founder25.8yrsUS$1.74m2.22%
$ 1.4m
Kazuko Matsuda
Senior VP6.9yrsUS$1.33m0.66%
$ 426.4k
Hideki Nagao
Independent Director8.6yrsUS$86.31k0%
$ 0
Carolyn Beaver
Independent Director5.7yrsUS$86.31k0%
$ 0
Christopher Breder
Lead Scientific Advisory Boardless than a yearNessun datoNessun dato
Nicole Lemerond
Independent Director2.8yrsUS$86.31k0%
$ 0
6.3yrs
Durata media
68yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MNOV sono considerati esperti (durata media dell'incarico 6.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/21 08:32
Prezzo dell'azione a fine giornata2026/06/18 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

MediciNova, Inc. è coperta da 8 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jason KolbertD. Boral Capital LLC.
Lander Egaña-GorroñoH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets